Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Elite control of HIV Infection: implications for vaccines and treatment.

Walker BD.

Top HIV Med. 2007 Aug-Sep;15(4):134-6. Review.

2.

Elucidating the elite: mechanisms of control in HIV-1 infection.

O'Connell KA, Bailey JR, Blankson JN.

Trends Pharmacol Sci. 2009 Dec;30(12):631-7. doi: 10.1016/j.tips.2009.09.005. Review.

PMID:
19837464
3.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
4.
5.

Incorporating novel virologic tests into clinical practice.

Daar ES.

Top HIV Med. 2007 Aug-Sep;15(4):126-9. Review.

6.

Update on cardiovascular complications in HIV infection.

Currier JS.

Top HIV Med. 2009 Jul-Aug;17(3):98-103. Review.

7.

HIV disease progression: immune activation, microbes, and a leaky gut.

Douek D.

Top HIV Med. 2007 Aug-Sep;15(4):114-7. Review.

8.

The challenges of host and viral diversity in HIV vaccine design.

Brander C, Frahm N, Walker BD.

Curr Opin Immunol. 2006 Aug;18(4):430-7. Epub 2006 Jun 13. Review.

PMID:
16777397
9.

Elite HIV controllers: myth or reality?

Saksena NK, Rodes B, Wang B, Soriano V.

AIDS Rev. 2007 Oct-Dec;9(4):195-207. Review.

PMID:
18219363
10.

Elite controllers as a model of functional cure.

Autran B, Descours B, Avettand-Fenoel V, Rouzioux C.

Curr Opin HIV AIDS. 2011 May;6(3):181-7. doi: 10.1097/COH.0b013e328345a328. Review.

PMID:
21460722
11.

Non--AIDS-defining malignancies in HIV.

Mitsuyasu RT.

Top HIV Med. 2008 Oct-Nov;16(4):117-21. Review.

12.

Elite control of HIV infection: implications for vaccine design.

Baker BM, Block BL, Rothchild AC, Walker BD.

Expert Opin Biol Ther. 2009 Jan;9(1):55-69. doi: 10.1517/14712590802571928 . Review.

13.

Pathogenesis and treatment of lipodystrophy: what clinicians need to know.

Sattler FR.

Top HIV Med. 2008 Oct-Nov;16(4):127-33. Review.

14.
15.

Emerging resistance profiles of newly approved antiretroviral drugs.

Daar ES.

Top HIV Med. 2008 Oct-Nov;16(4):110-6. Review.

16.

Combining drug and immune therapy: a potential solution to drug resistance and challenges of HIV vaccines?

Endsley AN, Salama NN, Ho RJ.

Curr HIV Res. 2008 Sep;6(5):401-10. Review.

PMID:
18855650
17.

Current status of HIV infection: a review for non-HIV-treating physicians.

Knoll B, Lassmann B, Temesgen Z.

Int J Dermatol. 2007 Dec;46(12):1219-28. doi: 10.1111/j.1365-4632.2007.03520.x. Review.

PMID:
18173512
18.

Late presentation of HIV-infected individuals.

Battegay M, Fluckiger U, Hirschel B, Furrer H.

Antivir Ther. 2007;12(6):841-51. Review.

PMID:
17926639
19.

Renal dysfunction and tenofovir toxicity in HIV-infected patients.

Szczech LA.

Top HIV Med. 2008 Oct-Nov;16(4):122-6. Review.

20.

HIV vaccines under study.

Ravanfar P, Mendoza N, Satyaprakash A, Jordan BI.

Dermatol Ther. 2009 Mar-Apr;22(2):158-67. doi: 10.1111/j.1529-8019.2009.01228.x. Review.

PMID:
19335727

Supplemental Content

Support Center